<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Oxymetazoline (nasal): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Oxymetazoline (nasal): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Oxymetazoline (nasal): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12276" href="/d/html/12276.html" rel="external">see "Oxymetazoline (nasal): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="16035" href="/d/html/16035.html" rel="external">see "Oxymetazoline (nasal): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F9504215"><span class="drugH1">Brand Names: US</span>
<ul>
<li>12 Hour Decongestant [OTC];</li>
<li>12 Hour Nasal Decongestant [OTC];</li>
<li>12 Hour Nasal Relief Spray [OTC];</li>
<li>12 Hour Nasal Spray [OTC];</li>
<li>Afrin 12 Hour [OTC];</li>
<li>Afrin Menthol Spray [OTC];</li>
<li>Afrin Nasal Spray [OTC] [DSC];</li>
<li>Afrin NoDrip Extra Moisture [OTC];</li>
<li>Afrin NoDrip Original [OTC];</li>
<li>Afrin NoDrip Sinus [OTC];</li>
<li>Dristan Spray [OTC] [DSC];</li>
<li>FT Nasal Spray [OTC];</li>
<li>Long Lasting Nasal Spray [OTC];</li>
<li>Mucinex Childrens Stuffy Nose [OTC] [DSC];</li>
<li>Mucinex Sinus-Max Clear &amp; Cool [OTC];</li>
<li>Mucinex Sinus-Max Sinus/Allrgy [OTC];</li>
<li>Nasal Decongestant Spray [OTC];</li>
<li>Nasal Spray Max Strength [OTC];</li>
<li>QlearQuil [OTC];</li>
<li>Vicks Sinex 12 Hour Decongest [OTC];</li>
<li>Vicks Sinex Moisturizing [OTC];</li>
<li>Vicks Sinex Severe Decongest [OTC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F9507255"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Adrenergic Agonist Agent;</li>
<li>
                        Decongestant;</li>
<li>
                        Imidazoline Derivative</li></ul></div>
<div class="block doa drugH1Div" id="F9504424"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aa6069be-77fb-4807-b092-cbf82db43773">Nasal congestion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nasal congestion:</b>
<b>Intranasal:</b> Instill 2 to 3 sprays into each nostril twice daily (maximum dose: 2 doses/24 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration:</i> Generally limit to 3 to 5 days of consecutive use due to risk of rhinitis medicamentosa (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32707227','lexi-content-ref-25644617']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32707227','lexi-content-ref-25644617'])">Ref</a></span>). In patients with persistent symptoms despite use of first-line therapies, some guidelines suggest oxymetazoline may be offered in combination with an intranasal corticosteroid for up to 4 weeks with low risk of rhinitis medicamentosa (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32707227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32707227'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991514"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50988889"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F9504425"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F9504423"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="16035" href="/d/html/16035.html" rel="external">see "Oxymetazoline (nasal): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aa6069be-77fb-4807-b092-cbf82db43773">Nasal congestion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nasal congestion:</b> Children ≥6 years and Adolescents: 0.05% solution: Intranasal: Instill 2 to 3 sprays into each nostril twice daily; doses should be separated by 10 to 12 hours; maximum daily dose: 2 doses/24 hours; therapy should not exceed 3 days. <b>Note:</b> Intranasal not recommended for use in children &lt;6 years of age (especially in infants) due to CNS depression.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51151398"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51151399"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F9504406"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">There are no adverse reactions listed in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute coronary syndrome (Montastruc 2014), acute myocardial infarction (Rajpal 2014), angina pectoris (Shah 2018), cardiac arrhythmia (Shah 2018), hypertension (including hypertensive crisis) (Shah 2018, Loewen 2004), hypotension (Shah 2018), palpitations (Loewen 2004), syncope (Shah 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebrovascular accident (Cantu 2003), headache (including severe headache [thunderclap]) (Loewen 2004), subarachnoid hemorrhage (Cantu 2003)</p></div>
<div class="block coi drugH1Div" id="F9504221"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">OTC labeling: When used for self-medication, do not use for more than 3 days.</p></div>
<div class="block war drugH1Div" id="F9504222"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Local nasal effects: Temporary discomfort such as burning, stinging, sneezing, or an increased nasal discharge may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Rebound nasal congestion: Frequent or prolonged use may cause nasal congestion to recur or worsen.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with hypertension or heart disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disease: Use with caution in patients with thyroid disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Accidental ingestion: Accidental ingestion by children of over-the-counter (OTC) imidazoline-derivative eye drops and nasal sprays may result in serious harm. Serious adverse reactions (eg, coma, bradycardia, respiratory depression, sedation) requiring hospitalization have been reported in children ≤5 years of age who had ingested even small amounts (eg, 1 to 2 mL). Contact a poison control center and seek emergency medical care immediately for accidental ingestion (FDA Drug Safety Communication 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Self-medication (OTC use): When used for self-medication (OTC), do not exceed recommended dosages; use of this container by more than one person may spread infection.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878754"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F9504460"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Nasal, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12 Hour Decongestant: 0.05% (30 mL) [contains benzalkonium chloride, edetate (edta) disodium dihydrate, polyethylene glycol (macrogol), propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12 Hour Nasal Decongestant: 0.05% (30 mL) [contains benzalkonium chloride, benzyl alcohol, edetate (edta) disodium, polyethylene glycol (macrogol)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12 Hour Nasal Relief Spray: 0.05% (15 mL [DSC], 30 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12 Hour Nasal Spray: 0.05% (30 mL) [contains benzalkonium chloride]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Afrin 12 Hour: 0.05% (30 mL) [contains benzalkonium chloride, disodium edta, polyethylene glycol (macrogol), propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Afrin Menthol Spray: 0.05% (15 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Afrin Nasal Spray: 0.05% (15 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Afrin Nasal Spray: 0.05% (15 mL [DSC], 20 mL [DSC], 30 mL [DSC]) [contains benzalkonium chloride, disodium edta]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Afrin NoDrip Extra Moisture: 0.05% (15 mL) [contains benzalkonium chloride]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Afrin NoDrip Original: 0.05% (15 mL) [contains benzalkonium chloride]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Afrin NoDrip Sinus: 0.05% (15 mL) [contains benzalkonium chloride, menthol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dristan Spray: 0.05% (15 mL [DSC]) [contains benzalkonium chloride, disodium edta]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Nasal Spray: 0.05% (30 mL) [contains benzalkonium chloride, edetate (edta) disodium, menthol, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Long Lasting Nasal Spray: 0.05% (30 mL) [contains benzalkonium chloride]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mucinex Childrens Stuffy Nose: 0.05% (22 mL [DSC]) [contains benzalkonium chloride, disodium edta, menthol, polysorbate 80, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mucinex Sinus-Max Clear &amp; Cool: 0.05% (22 mL) [contains benzalkonium chloride, edetate (edta) disodium, menthol, polyethylene glycol (macrogol), polysorbate 80, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mucinex Sinus-Max Sinus/Allrgy: 0.05% (22 mL) [contains benzalkonium chloride, disodium edta, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nasal Decongestant Spray: 0.05% (15 mL) [contains benzalkonium chloride, benzyl alcohol, edetate (edta) disodium, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nasal Decongestant Spray: 0.05% (15 mL, 30 mL) [contains benzalkonium chloride, edetate (edta) disodium, polyethylene glycol (macrogol), propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nasal Spray Max Strength: 0.05% (30 mL) [gluten free; contains benzalkonium chloride, benzyl alcohol, disodium edta]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">QlearQuil: 0.05% (15 mL) [contains benzalkonium chloride, disodium edta]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vicks Sinex 12 Hour Decongest: 0.05% (15 mL) [contains benzalkonium chloride, disodium edta]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vicks Sinex Moisturizing: 0.05% (15 mL) [contains benzalkonium chloride, benzyl alcohol, edetate (edta) disodium, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vicks Sinex Severe Decongest: 0.05% (15 mL) [contains benzalkonium chloride, benzyl alcohol, edetate (edta) disodium, menthol, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (30 mL)</p></div>
<div class="block geq drugH1Div" id="F9504218"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16322391"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Afrin Menthol Spray Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per mL): $0.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Afrin NoDrip Original Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per mL): $0.38</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Giltuss Severe Sinus Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per mL): $0.49</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Mucinex Sinus-Max Clear &amp; Cool Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per mL): $0.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Mucinex Sinus-Max Sinus/Allrgy Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per mL): $0.40</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F49103785"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Intranasal:</b> For intranasal use only. Shake well before use (varies by product; also refer to manufacturer’s labeling). Before using for the first time, prime the pump by firmly depressing the rim several times. Keep head upright and insert nozzle into nostril, depress rim firmly, and inhale deeply.</p></div>
<div class="block admp drugH1Div" id="F52614394"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Intranasal: For intranasal use only. Shake well before use. Before using for the first time, follow directions per labeling for any applicable priming. Keep head upright (do not tilt) during administration. Insert nozzle/applicator into nostril. Spray or apply drops into each nostril.</p></div>
<div class="block use drugH1Div" id="F9504219"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Nasal congestion: </b>Temporary relief of nasal congestion (due to a cold, hay fever, or other upper respiratory allergies) and sinus congestion/pressure.</p></div>
<div class="block off-label drugH1Div" id="F50932409"><span class="drugH1">Use: Off-Label: Adult</span><p>Topical vasoconstriction in nasal procedures</p></div>
<div class="block mst drugH1Div" id="F9504320"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Oxymetazoline may be confused with oxymetholone</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Afrin may be confused with aspirin</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Afrin (oxymetazoline) may be confused with Afrin (saline)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Neo-Synephrine (oxymetazoline) may be confused with Neo-Synephrine (phenylephrine, nasal)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Accidental ingestion: Serious adverse reactions (eg, coma, bradycardia, respiratory depression, sedation) requiring hospitalization have been reported in children ≤5 years of age who have accidentally ingested even small amounts (eg, 1-2 mL) of imidazoline-derivative (ie, tetrahydrozoline, oxymetazoline, or naphazoline) eye drops or nasal sprays. Store these products out of reach of children at all times. Contact poison control or seek medical attention if accidental ingestion occurs.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299804"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F9504410"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atropine (Systemic): May enhance the hypertensive effect of Alpha1-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: May enhance the hypertensive effect of Alpha1-Agonists. Management: Consider alternatives to this combination when possible. If combined, monitor for hypertension and tachycardia, and do not coadminister these agents for more than 10 days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): May enhance the vasoconstricting effect of Alpha1-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: Decongestants (Nasally Administered) may diminish the therapeutic effect of Esketamine.  Management: Patients who require a nasal decongestant on an esketamine dosing day should administer the nasal decongestant at least 1 hour before esketamine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: Decongestants may decrease the serum concentration of FentaNYL. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iobenguane Radiopharmaceutical Products: Alpha1-Agonists may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the hypertensive effect of Alpha1-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to linezolid specific monographs for details.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pergolide: May enhance the hypertensive effect of Alpha1-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the therapeutic effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the therapeutic effect of Alpha1-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zavegepant: Decongestants (Nasally Administered) may decrease the serum concentration of Zavegepant.  Management: Avoid the concurrent administration of intranasal decongestants with zavegepant. If combined use is unavoidable, intranasal decongestants should be administered at least 1 hour after zavegepant administration.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F12711040"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse fetal/neonatal events have been noted in case reports following large doses or extended use of oxymetazoline nasal spray in the first trimester of pregnancy (Baxi 1985; Holm 1985; Menezes 2016). Fetal blood flow was not found to be affected by a one-time dose of oxymetazoline in noncomplicated, third trimester pregnancies (Rayburn 1990).</p>
<p style="text-indent:0em;margin-top:2em;">Decongestants are not recommended for the treatment of rhinitis during pregnancy (BSACI [Scadding 2017]). Use of oxymetazoline nasal spray can be considered if acute relief is needed (Mazzotta 1999).</p></div>
<div class="block brc drugH1Div" id="F49944664"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">If a decongestant is needed, nasal preparations may be preferred over systemic agents in nursing women (Anderson 2000).</p></div>
<div class="block pha drugH1Div" id="F9504416"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Stimulates alpha-adrenergic receptors in the arterioles of the nasal mucosa to produce vasoconstriction</p></div>
<div class="block phk drugH1Div" id="F9504418"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Within 10 minutes (Chua 1989)</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Up to 12 hours (Chua 1989)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F11390235"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Afrin | Duration | Iliadin | Nasivin | Oxylin | Utabon</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Alosol | Isly | Lidil | Lidil Spray | Oxiler d | Panoxi | Vick sinex</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Nasiben sanft | Nasivin | Wick sinex | Wick Sinexaloe</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Amcal decongestant | Apohealth decongestant | Blooms the chemist decongestant | Chemists own decongestant | Chemplus decongestant | Colden | Decongestant | Demazin 12 hour relief nasal spray | Dimetapp | Discount drug stores decongestant | Drixine | Hs | Logicin rapid relief | Mendeleev nasal decongestant | O/n | Pharmacy action nasal decongestant | Pharmacy care decongestant | Pharmacy health decongestant nasal spray | Priceline decongestant | Sudafed nasal decongestant | Trust decongestant | Twp nasal decong | Vicks sinex | Wagner health Wagner health Nasal Decongestant | Your pharmacy decongestant</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Afrin | Azolin | Congenil | G con | Iliadin | Nasalox | Natazol | Nazolin | Oxydrop | Oxymet | Oxynex | Rynex | Xylocon</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Nesivine | Rhino humex | Vicks sinex</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Aturgyl | Respibien</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Afrin | Afrin nd | Nazopass | Resoxym | Vicks sinex aloe and eucaliptus</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Afrin | Aturgyl | Aturgyl nf | Cloridrato de oximetazolina | Desfrin | Freenal | Nasivin | Oxifrin | Oxilin | Rinidal | Rinitin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Nasivin</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Afrine | Afrine oftalmico | Iliadin | Isly | Oxiler d | Oxilin | Xenius</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bo fen lin | Da fen lin | Di li tuo | Feng lang | Oxylin | Oxymetazoline</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Afrin | Clarivis | Drixine | Nafazol | Nasivin | Nasivin baby | Nasivin infantil | Openxy | Oxiflash | Oxifrin adulto | Oximetazolina | Oximetazolina clorhidrato | Oximetazolina Hcl | Oximisyn | Rhinofrenol | Wasserfrin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Afrin | Nasivin | Nasivin Sensitive | Oxamet | Sinex | Sinex vicks aloe a eukalyptus</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Em-eukal mono | Em-medical | Nasivin | Nasivin ohne Konservierungsstoffe | Nasivin zink | Wick sinex</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Afrin | Afrin Lub | Alcamin | Iliadin | Lidil | Nasin | Oxilina | Respibien | Utabon | Visina LR</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Afrin | Ocuclear | Openxy | Oximetazolina hcl mk | Rinex</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Afrin glycerol | Lekonil | Nazol | Wick sinex</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Afrin | Iliadin | Oxymet | Oxymetazoline MUP</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Alerfrin | Aurorespir | Corilisina | Cuvenax | Descongestan | Egarone oximetazol | Ilvinax | Interfrin | Lairesp | Nasolina | Nebulicina | Normonasal | Novag rino | Oftinal | Okalrinus | Oximetazolina edigen | Oximetazolina farlline | Oximetazolina tecnimede | Respibien | Respibien Freshmint | Respir | Rinotec | Serranasal | Sinexsensi | Utabon</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Nasalox</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Drixin | Iliadin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Aturgyl</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Afrazine | Asda nasal decongestant spray | Boots blocked nose relief | Nasivin | Oxymetazoline</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Ezixin | Ronal | Vicks sinex</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Afrin | Duration | Iliadin | Logicin rapid relief | Nasomist | Oxy nase | Respibien | Synus</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Operil | Operil p</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Afrin | Nasivin | Nasivin sanft | Wick sinex avera</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Afrin | Iliadin | Visine Long Range</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Afrazine | Neilmed Sinufrin | Vicks sinex</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Alrin | Rhinoclir | Sinulen</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Codylex nasal | Febrex plus - ns | Lemolate | Maxtra o | Medinoze junior | Naselin | Nasivion | Nazoden | Otrivin-o | Oxylin | Oxymet | Oxyspray | Rhinojet | Rhinoset oxy | Sinarest | Sinoxy | Sudin | Tencol | Vicks sinex | Vilco nasal drops | Xynose | Xynose kit | Zoamet | Zomet</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Nazordin</span>;</li>
<li>
<span class="countryCode">(IR)</span> <span class="country">Iran, Islamic Republic of</span><span class="countrySeparator">: </span><span class="drugName">Rinozoline</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Actifed nasale | Coricidin | Leviorinil | Narielle | Neo borocillina nasale | Ossimetazolina MG | Oxilin | Rino calyptol | Vicks sinex</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Iliadin | Nasivin | Oxazoline</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Nasivin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Iliadin | Iliadin baby nose drops | Iliadin kids nose drops | Nasivin | Nasivion | Nazolin | Oxylin | Utabon adult | Utabon paediatric</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cleanb | Green nasal | Otrivin s | Oxyaid | Oxycozal | Oxyzol | Respibien | Siwontachoa | Synus</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Duration | Iliadin | Nasivin | Utabon</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Alerjon | Duration | Nasivin | Utabon</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Afrin | End-oksimetazolin | Exnos | Lekonil | Lekonil p | Nasivin | Nasol | Nazol | Resoxym</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Nasivin | Nesivine | Vicks sinex</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Afrin | Afrin Chamomile | Alrin | Lekonil | Lekonil p | Nasivin | Nasol | Nazol | Oxamet | Sinex</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Nasivine</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Afrin | Afrin Lub | Afrin no drip | Afrin no drip cse | Afrin no drip ori | Collifrin | Iliadin | Lubyox | Naztril | Ocuclear | Oximetazolina | Oxylin | Ritrila | Virindrez</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Afrin | Axcel Oxymetazoline | Iliadin | Kotrin | Oxazoline | Oxy nase | Oxymetazoline wintac | Utabon | Xylocon</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Iliadin baby nose drops | Iliadin decongestant nose spray adults | Iliadin kids nose drops | Kinglion oxymetazoline hydrochloride | Nasic</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Nasivin | Oxylin | Vicks sinex</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Iliadin | Nasiben baby sanft | Nasivin | Rhinox</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apohealth decongestant | At-eze | Dimetapp | Drixine | Mucinex Sinus | Pharmacy health decongestant nasal spray | Priceline decongestant | Sinex | Sudafed nasal decongestant | Vicks sinex | Your pharmacy decongestant</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Afrin | Clarivis | Eyeston | Iliadin | Oximetazolina | Oxylin | Respibien | Rinerge | Rinophar | Rynat d | Rynatan d</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Drixine | Iliadin | Nasivin | Nasofix | Nasofree | Oxy nase</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Naldin | Oxylin | Rinerge</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Acatar | Acatar care | Acatar care kids | Acatar control | Afrin | Afrin nd | Nasivin | Nasivin baby | Nasivin classic | Nasivin kids | Nasivin soft | Nosox | Nosox classic | Nosox junior | Oxalin | Oxymetazolin apteo | Resoxym | Vicks sinex aloes i eukaliptus</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Afrin | Afrin All Night No Drip | Afrin childrens | Afrin no drip | Afrin severe congestion | Bausch&amp;Lomb Nasal | Genasal la | Giltuss severe sinus | Mucinex children's stuffy nose | Mucinex sinus max full force | Mucinex sinus max moisture smart | Mucinex sinus max sinus &amp; allergy | Nostrilla | Nostrilla 12 hour nasal decongestant | Ocuclear | Oxymetazoline HCL | Sudafed om | Sudafed Om Sinus Congestion | Vicks Early Defense</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Alerjon | Bisolspray | Ilvico respir | Nasarox | Nasex | Nasitrim | Nasorhinathiol | Oximetazolina farmoz | Oxylin | Rinerge | Sinexsensi | Zolinol</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Rimevax | Rinarin</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Nasivin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Afrin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Afrin | Afrin extro | Afrin moisturizing | Fervex nasal | Knoxpray | Lekonil | Nasivin | Nasivin Sensitive | Nazol | Nazol advance | Nazospray | Nesopin | Otrivin express | Oxyfrin | Oxymetazoline | Oxymetazoline akrikhin | Oxymethazoline | Rankof rino | Rinostop | Rinostop extra | Sanorinchik | Sialor Rhino | Vicks active sinex | Vicks sinex</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Iliadin | Nasivin | Oxylin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Drixin | Iliadin | Nasin | Nezepro | Nezeril | Vicks sinex</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Afrin | Iliadin | Kotrin | Nazolin | Oxy nase | Vicks sinex</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Afrin | Nasivin | Nazopass | Operil</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Afrin | Nasivin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Feenoze | Iliadin | Metzodin | Nasil | Omelin light | Oxylin | Oxymet | Phindroz | Sifrin nebulizer</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Aturgyl</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Burazin | Iliadin | Oksinazal | Oxynaz | Rhinfant</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Anjet j | Berton | Bichanshun | Cortimin | Ephrine | Libiton | Masalax | Nasaton | Nasline | Nasolax | Nazal m | Nezeril | Oxymetazoline | Pitosan | Respibien | Rhinly | Sindecon | Suton-p | Swinin | Win-min | Win-Way</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Afrin | Loratek | Nasalong kids | Nasivin | Nasivin Sensitive | Nasol | Nasol kids | Nazalong | Nazo | Noxprey | Noxprey active | Noxprey Dytiachyi | Noxprey malyuk | Rhinoxil n | Rinazal extra | Rinazoline | Rint | Sinumax</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Iliadin | Sinarest | Sinarest pd</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Alergidina | Lidil | Oxiler d | Oxilin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Afrin | Airfen | Clarix | Drixine | Nasin | Oximetazolina | Solarsal</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Bicol B | Oxacol</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Allergex | Drinasal paediatric | Drixine | Iliadin | Oxylin | Oxymetazoline | Oxymist | Oxyspray moisturising | Sinustop | Sparkling white | Vicks sinex decon | Zadin</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Nasivion | Oxy nase</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Afrin Original (oxymetazoline hydrochloride) [prescribing information]. Whippany, NJ: Bayer HealthCare LLC: received August 2019.</div>
</li>
<li>
<div class="reference">
                  Afrin Pump Mist (oxymetazoline hydrochloride) [prescribing information]. Whippany, NJ: Bayer HealthCare LLC: received August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11155604">
<a name="11155604"></a>Anderson PO. Decongestants and milk production. <i>J Hum Lact</i>. 2000;16(4):294.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/11155604/pubmed" id="11155604" target="_blank">11155604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2416220">
<a name="2416220"></a>Baxi LV, Gindoff PR, Pregenzer GJ, et al, "Fetal Heart Rate Changes Following Maternal Administration of a Nasal Decongestant," <i>Am J Obstet Gynecol</i>, 1985, 153(7):799-800.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/2416220/pubmed" id="2416220" target="_blank">2416220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12791938">
<a name="12791938"></a>Cantu C, Arauz A, Murillo-Bonilla LM, López M, Barinagarrementeria F. Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs. <i>Stroke</i>. 2003;34(7):1667-1672. doi:10.1161/01.STR.0000075293.45936.FA<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/12791938/pubmed" id="12791938" target="_blank">12791938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2647163">
<a name="2647163"></a>Chua SS, Benrimoj SI, Triggs EJ. Pharmacokinetics of non-prescription sympathomimetic agents. <i>Biopharm Drug Dispos</i>. 1989;10(1):1-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/2647163/pubmed" id="2647163" target="_blank">2647163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32707227">
<a name="32707227"></a>Dykewicz MS, Wallace DV, Amrol DJ, et al; Workgroup Contributors. Rhinitis 2020: a practice parameter update.<i> J Allergy Clin Immunol</i>. 2020;146(4):721-767. doi:10.1016/j.jaci.2020.07.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/32707227/pubmed" id="32707227" target="_blank">32707227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>Food and Drug Administration. FDA Drug Safety Communication: Serious adverse events from accidental ingestion by children of over-the-counter eye drops and nasal sprays. U.S. Food and Drug Administration. October 25, 2012. Available at <a href="http://www.fda.gov/Drugs/DrugSafety/ucm325257.htm" target="_blank">http://www.fda.gov/Drugs/DrugSafety/ucm325257.htm</a>. Accessed September 5, 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21271600">
<a name="21271600"></a>Higgins TS, Hwang PH, Kingdom TT, Orlandi RR, Stammberger H, Han JK. Systematic review of topical vasoconstrictors in endoscopic sinus surgery. <i>Laryngoscope</i>. 2011;121(2):422-432. doi: 10.1002/lary.21286.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/21271600/pubmed" id="21271600" target="_blank">21271600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3998934">
<a name="3998934"></a>Holm IA and Clarren SK, "An Unusual Pattern of Malformation Associated With Gestational Exposure to Nasal Spray," <i>J Pediatr</i>, 1985, 106(5):860-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/3998934/pubmed" id="3998934" target="_blank">3998934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8182859">
<a name="8182859"></a>Johns ME, Richtsmeier WJ. Otolaryngology--head and neck surgery. <i>JAMA</i>. 1994;271(21):1698-1700.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/8182859/pubmed" id="8182859" target="_blank">8182859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15367461">
<a name="15367461"></a>Loewen AH, Hudon ME, Hill MD. Thunderclap headache and reversible segmental cerebral vasoconstriction associated with use of oxymetazoline nasal spray. <i>CMAJ</i>. 2004;171(6):593-594. doi:10.1503/cmaj.1040631<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/15367461/pubmed" id="15367461" target="_blank">15367461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10230583">
<a name="10230583"></a>Mazzotta P, Loebstein R, Koren G. Treating allergic rhinitis in pregnancy. Safety considerations. <i>Drug Saf</i>. 1999;20(4):361‐375. doi:10.2165/00002018-199920040-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/10230583/pubmed" id="10230583" target="_blank">10230583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27087030">
<a name="27087030"></a>Menezes GA, Araujo Júnior E, Lopes J, Belmonte S, Tonni G<sup>4</sup>, Werner H. Prenatal diagnosis and physical model reconstruction of agnathia-otocephaly with limb deformities (absent ulna, fibula and digits) following maternal exposure to oxymetazoline in the first trimester. <i>J Obstet Gynaecol Res</i>. 2016;42(8):1016-1020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/27087030/pubmed" id="27087030" target="_blank">27087030</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25451367">
<a name="25451367"></a>Montastruc F, Montastruc G, Taudou MJ, Olivier-Abbal P, Montastruc JL, Bondon-Guitton E. Acute coronary syndrome after nasal spray of oxymetazoline. <i>Chest</i>. 2014;146(6):e214-e215. doi:10.1378/chest.14-1873<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/25451367/pubmed" id="25451367" target="_blank">25451367</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Mucinex Children's Stuffy Nose Spray (oxymetazoline hydrochloride) [prescribing information]. Parsippany, NJ: Reckitt Benckiser; March 2018.</div>
</li>
<li>
<div class="reference">
                  Mucinex Sinus-Max Sinus &amp; Allergy (oxymetazoline hydrochloride) [prescribing information]. Parsippany, NJ: RB Health (US); received March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2196495">
<a name="2196495"></a>Rayburn WF, Anderson JC, Smith CV, et al, "Uterine and Fetal Doppler Flow Changes From a Single Dose of a Long-Acting Intranasal Decongestant," <i>Obstet Gynecol</i>, 1990, 76(2):180-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/2196495/pubmed" id="2196495" target="_blank">2196495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24405558">
<a name="24405558"></a>Rajpal S, Morris LA, Akkus NI. Non-ST-elevation myocardial infarction with the use of oxymetazoline nasal spray. <i>Rev Port Cardiol</i>. 2014;33(1):51.e1-51.e514. doi:10.1016/j.repc.2013.07.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/24405558/pubmed" id="24405558" target="_blank">24405558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30239057">
<a name="30239057"></a>Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). <i>Clin Exp Allergy</i>. 2017;47(7):856‐889. doi:10.1111/cea.12953<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/30239057/pubmed" id="30239057" target="_blank">30239057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25644617">
<a name="25644617"></a>Seidman MD, Gurgel RK, Lin SY, et al; Guideline Otolaryngology Development Group. AAO-HNSF. Clinical practice guideline: allergic rhinitis. <i>Otolaryngol Head Neck Surg</i>. 2015;152(1)(suppl):S1-S43. doi:10.1177/0194599814561600<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/25644617/pubmed" id="25644617" target="_blank">25644617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28901959">
<a name="28901959"></a>Shah S, Patel K, Gambhir HS. Oxymetazoline-induced asthma. <i>Am J Ther</i>. 2018;25(6):e681-e682. doi:10.1097/MJT.0000000000000628<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/28901959/pubmed" id="28901959" target="_blank">28901959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8233500">
<a name="8233500"></a>Tarver CP, Noorily AD, Sakai CS. A comparison of cocaine vs. lidocaine with oxymetazoline for use in nasal procedures. <i>Otolaryngol Head Neck Surg</i>. 1993;109(4):653-659. doi: 10.1177/019459989310900404.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/8233500/pubmed" id="8233500" target="_blank">8233500</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Vicks Sinex (oxymetazoline hydrochloride) [prescribing information]. Cincinnati, OH: Procter &amp; Gamble; received August 31, 2016.</div>
</li>
<li>
<div class="reference">
                  Vicks Sinex Moisturizing (oxymetazoline hydrochloride) [prescribing information]. Cincinnati, OH: Procter &amp; Gamble; received August 31, 2016.</div>
</li>
<li>
<div class="reference">
                  Vicks Sinex Severe (oxymetazoline hydrochloride) [prescribing information]. Cincinnati, OH: Procter &amp; Gamble; received October 2019.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9896 Version 352.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
